Clinical Trial Detail

NCT ID NCT02892123
Title Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Zymeworks Inc.
Indications

Advanced Solid Tumor

gastroesophageal junction adenocarcinoma

Her2-receptor positive breast cancer

stomach carcinoma

Therapies

Capecitabine + ZW25

ZW25

Paclitaxel + ZW25

Vinorelbine + ZW25

Age Groups: adult senior

Additional content available in CKB BOOST